Anavex Life Sciences Announced That The First Patient In Its Phase 2 Study Of ANAVEX3-71 For Schizophrenia Has Been Screened Ahead Of Schedule
Anavex Life Sciences Announced That The First Patient In Its Phase 2 Study Of ANAVEX3-71 For Schizophrenia Has Been Screened Ahead Of Schedule
Anavex Life Sciences 宣佈，其 ANAVEX3-71 精神分裂症 2 期研究的第一位患者已提前接受篩查
Anavex Life Sciences Announced That The First Patient In Its Phase 2 Study Of ANAVEX3-71 For Schizophrenia Has Been Screened Ahead Of Schedule
Anavex Life Sciences 宣佈，其 ANAVEX3-71 精神分裂症 2 期研究的第一位患者已提前接受篩查
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。